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glomerular filtration rate ratio in patients with
chronic kidney disease: a cross-sectional study
Yen-chung Lin1,2,3*, Nisha Bansal3, Eric Vittinghoff4, Alan S Go4,5 and Chi-yuan Hsu3Abstract
Background: Creatinine secretion, as quantified by the ratio of creatinine clearance (CrCl) to glomerular filtration
rate (GFR), may introduce another source of error when using serum creatinine concentration to estimate GFR. Few
studies have examined determinants of the CrCl/GFR ratio. We sought to study whether higher levels of
albuminuria would be associated with higher, and being non-Hispanic black with lower, CrCl/GFR ratio.
Methods: We did a cross-sectional analysis of 1342 patients with chronic kidney disease from the Chronic Renal
Insufficiency Cohort (CRIC) who had baseline measure of iothalamate GFR (iGFR) and 24-hour urine collections.
Our predictors included urine albumin as determined from 24-hour urine collections (categorized as: <30, 30-299,
300-2999 and ≥3000 mg), and race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic). Our outcome was
CrCl/iGFR ratio, a measure of creatinine secretion.
Results: Mean iGFR was 48.0 ± 19.9 mL/min/1.73 m2, median albuminuria was 84 mg per day, and 36.8% of the
study participants were non-Hispanic black. Mean CrCl/iGFR ratio was 1.19 ± 0.48. There was no association between
the CrCl/iGFR ratio and urine albumin (coefficient 0.11 [95% CI−0.01-0.22] for higest verus lowest levels of albuminuria,
p = 0.07). Also, there was no association between race/ethnicity and CrCl/iGFR ratio (coefficient for non-Hispanic blacks
was−0.03 [95% CI−0.09-0.03] compared with whites, p = 0.38).
Conclusions: Contrary to what had been suggested by prior smaller studies, CrCl/GFR ratio does not vary with degree
of proteinuria or race/ethnicity. The ratio is also closer to 1.0 than reported by several frequently cited reports in
the literature.
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In clinical practice and research studies, kidney function
is most often estimated using concentration of serum
creatinine, an endogenous filtration marker. This is based
on the assumption that creatinine clearance (CrCl) ap-
proximates GFR. In considering the limitations of serum
creatinine-based estimates of glomerula filtration rate
(GFR), much attention has been given to problems stem-
ming from variations in creatinine production which may
be reduced as a result of factors such as malnutrition,* Correspondence: yclin0229@tmu.edu.tw
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reproduction in any medium, provided the oradvanced age or liver disease. Less attention has been
given to the fact that creatinine is cleared by the kidneys
not only by filtration but also by tubular secretion. So vari-
ations in creatinine secretion may introduce another
source of error when using serum creatinine concentra-
tion to estimate kidney function.
Prior research has shown or suggested that several fac-
tors influence the rate of tubular secretion of creatinine
which can be quantified as the CrCl/GFR ratio [1]. CrCl/
GFR ratio increases as GFR decreases [2,3] (i.e. tubular
secretion plays an increasing important role in renal ex-
cretion of creatinine as GFR falls). Other studies have
reported that patients with high levels of proteinuria
may have high CrCl/GFR ratio. For example, one study
reported that patients with nephrotic range proteinuria. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creatinine of 36 ml/min/1.73 m2 (vs. 24 ml/min/1.73 m2
for those with less severe nephrotic syndrome) [4]. Finally,
some studies have suggested that African-American
patients may have lower CrCl/GFR ratio than non-African
Americans [5,6].
However, these prior studies of the relation between
CrCl and GFR have been limited by small sample sizes
and inclusion of only a limited spectrum of kidney disease
(such as only patients with glomerular disease) [7], and
lack of calibration of serum creatinine measurements
which render results harder to interpret as systemic errors
in serum creatinine measurements may lead to higher or
lower CrCl values [6]. In addition, some studies quantified
urine protein via excretion of total protein rather than al-
bumin. Measurement of total urine protein is not possible
to standardize and is increasingly considered a suboptimal
meter of renal dysfunction compared with measurement
of albuminuria [8,9].
To address these knowledge gaps, we explored factors
which influence CrCl/GFR ratio in a large diverse cohort
of patients with chronic kidney disease (CKD), who had
calibrated serum creatinine measurements and quantifi-
cation of 24-hour urine albumin [10,11]. We a priori
wanted to examine whether greater degree of albumi-
nuria was associated with higher and being non-Hispanic
black with lower CrCl/GFR ratio.
Methods
Study population
We used baseline data from a subset of participants in
the Chronic Renal Insufficiency Cohort (CRIC) study.
CRIC is a multicenter prospective cohort sponsored by
the National Institutes of Diabetes, Digestive and Kidney
Disease (NIDDK) that enrolled patients from seven clin-
ical centers throughout the United States. The design
and baseline characteristics of the CRIC cohort (includ-
ing rationale for inclusion and exclusion criteria) have
been published [10,12]. Briefly, men and women be-
tween the ages of 21 and 74 were eligible for the study if
they had reduced estimated GFR, based on Modification
of Diet in Renal Disease (MDRD) study equation. Inclu-
sion criteria were estimated GFR 20-70 ml/min per
1.73 m2 for person aged 21-44 years, 20-60 ml/min per
1.73 m2 for persons aged 45-64 years, and 20-50 ml/min
per 1.73 m2 persons aged 65-74 years. Exclusion criteria
included prior renal transplantation, polycystic kidney
disease, multiple myeloma, recent use of immunosuppres-
sion, and severe comorbid illnesses, such as cirrhosis, HIV
disease, and severe (New York Heart Association class III
or IV) heart failure. A weighted random sample of ap-
proximately one third of the cohort (referred to as the
subcohort) was assigned to undergo additional, more in-
tensive testing, including 125I-iothalamate clearance studiesto measure GFR. Enrollment started July 2003 and ended
March 2007. Additional enrollment of Hispanic par-
ticipants continued through August 2008 in one center
(“Hispanic CRIC”). Of the 3939 participants in CRIC, we
included in our study only the 1423 patients who partici-
pated in sub-study of 125I-iothalamate clearance. After ex-
cluding 81 enrollees who were missing 24-hour urine
albumin, our final study sample was 1342.
Measures of kidney function
Our study sample underwent direct GFR measurement
by urinary clearance of 125I-iothalamate (iGFR). iGFR
was conducted using a protocol similar to that in prior
studies [11,13]. Briefly, after a water load and admin-
istration of saturated solution of potassium iodine
(SSKI), 125I-iothalamate was injected subcutaneously. After
a 60-to 90-min waiting period, timed collections of urine
and serum were performed. Urine flow rate was main-
tained above 1 ml/min. The goal was to obtain four timed
urine collection periods bracketed by blood draws to meas-
ure plasma iothalamate levels (P). Concurrent urine counts
(U) and urine volumes (V) for each period were deter-
mined. GFR was calculated as weighted average UV/P and
corrected for body surface area. In CRIC, 88% of subcohort
enrollees had four or more urine collection periods, 6%
had three, and 5% had two or fewer. Due to increased
precision of measured GFR values with exclusion of
the first clearance period, this measure was used as the
reference standard in the analysis. The median coefficient
of variation (CV) for the iGFR was 9.7%, excluding the
first period [14].
Serum creatinine measurements were done in the CRIC
central laboratory at University of Pennsylvania on the
Hitachi Vitros 950 calibrated to the MDRD central labora-
tory at Cleveland Clinic [15] (because the original 4-
variable MDRD equation [16] was used as the entry criteria
for CRIC). For the analyses in this paper, we further cali-
brated the Cleveland Clinic creatinine to the standardized
IDMS-traceable serum creatinine value as Standardized
Cr = Cleveland Clinic serum creatinine*0.95 [17].
At baseline, urine creatinine and albumin excretion
were determined from a 24-hour urine collection. Urine
albumin was determined by immunoturbidometric assay
(Roche Diagnostics) and urine creatinine was done spec-
trophotometrically with Jaffe method (Roche Diagnostics).
The samples were rejected and re-collection attempted if
total urine volumes were below 500 cc or collection times
below 22 hours or more than 26 hours. All creatinine
clearances were calculated in this paper as UV/P with stan-
dardized serum creatinine measurements.
Assessments of predictors
We identified a priori several predictors of interest:
24-hour urine albumin, and self-reported race/ethnicity
Table 1 Characteristics of the study population (N = 1342)
Creatinine clearance (CrCl) (mL/min/1.73 m2) 54.9 ± 27.2
Iothalamate measured glomerular filtration
rate (iGFR) (mL/min/1.73 m2)
48.0 ± 19.9
CrCl/iGFR, mean ± SD 1.19 ± 0.48
CrCl/iGFR, median (25th-75th percentile) 1.15 (0.92-1.39)
24-hrs urine albumin (mg/24 hrs)
[median (25th-75th percentile)]
84 (11-643)
Age (years) 56.2 ± 12.2
Male, % 56.7%
Physical examinations
Body mass index (kg/m2) 31.3 ± 6.8
Body surface area (m2) 2.0 ± 0.3
Systolic blood pressure (mmHg) 129 ± 22









Peripheral vascular disease 5.7%
Stroke 8.0%
Current smoking, % 11.2%









Hematocrit (%) 37.4 ± 4.9
Albumin (g/dL) 3.9 ± 0.5
Serum creatinine (mg/dL) 1.61 ± 0.53
BUN (mg/dL) 29 ± 13
Triglyceride (mg/dL) 155 ± 112
LDL cholesterol (mg/dL) 103 ± 36
Fasting glucose (mg/dL) 113 ± 49
Hemoglobin A1C (%) 6.6 ± 1.6
hs-CRP (mg/L) [median (25th-75th percentile)] 2.2 (0.9-5.2)
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fined at the baseline CRIC visit. We classified 24-hr urine
albumin excretion as < 30 mg, 30-299 mg, and ≧300 mg
[9]. To allow for the detection of an effect in the
nephrotic range, we further divided the last group,
macro-albuminuria (also known as severely increased
albuminuria), in to above or below 3000 mg.
Assessments of outcome
The outcome variable of our study was the CrCl to iGFR
ratio. CrCl and iGFR were both expressed as ml/min
normalized to body surface area.
Statistical analysis
Baseline characteristics of CRIC subcohort participants
were described using mean ± standard deviation or me-
dian (25th-75th percentiles) for continuous variables and
number (percentage) for categorical variables.
Linear regression was used to test univariate associa-
tions between the CrCl/iGFR ratio and a comprehensive
list of baseline demographic and clinical characteristics
(Table 1). Characteristics that were found to be signifi-
cantly associated with CrCl/iGFR ratio were included in
subsequent multivariable models.
We explored the distribution of CrCl/iGFR ratio and
CrCl by quintiles of iGFR. Linear regression was to de-
termine the association between CrCl/iGFR ratio and
24-hour urine albumin and race/ethnicity in crude and
adjusted models. Because iGFR is in the denominator of
the outcome, we did not include it as a predictor.
In a sensitivity, analysis to reduce the skewness of re-
siduals, we examined log-transformed CrCl/iGFR ratio
as the outcome of interest.
All statistical analyses were performed using STATA
12 (STATA Corp, College Station, TX). A p-value < 0.05
was considered statistically significant.
Regulatory approval
De-identified data for this analysis were retrieved from
the National Institutes of Diabetes and Digestive and
Kidney Disease (NIDDK) Data Repository (https://
www.niddkrepository.org/niddk/home.doH) after appro-
priate institutional review board approval was obtained
(University of California San Francisco Committee on
Human Research IRB Number: 10-04231).
Results
Among the 1,342 participants in our study, the mean age
was 56 years, 57% were men, and 37% were non-Hispanic
black. The mean (± standard deviation [SD]) CrCl was
54.9 ± 27.2 mL/min/1.73 m2 and mean iGFR 48.0 ±
19.9 mL/min/1.73 m2 (Table 1). Mean CrCl/iGFR ratio
was 1.19 ± 0.47 and median CrCl/iGFR ratio was 1.15 (with
interquarile range [IQR] 0.92-1.39). The median time lapsebetween 24-hour urine collection and iGFR measurement
was 0 days (IQR 0 to 11 days) (mean time lapse 21 days).
We found, similar to prior studies, that patients with
lower iGFR had higher CrCl/iGFR ratios (Table 2).
Table 2 Creatinine clearance (CrCl), CrCl/iGFR, classified by quintiles of iothalamate-125 glomerular filtration rate
(iGFR) (N = 1342)
Quintiles of iGFR (ml/s/1.73 m2) iGFR (ml/min/1.73 m2), median (IQR) CrCl (ml/min/1.73 m2), median (IQR) CrCl/iGFR, median (IQR)
1 (N = 269) 24.8 (20.8—27.4) 31.7 (25.3—39.3) 1.33 (1.06—1.62)
2 (N = 268) 35.7 (33.0—38.5) 42.4 (33.6—51.4) 1.20 (0.94—1.47)
3 (N = 269) 45.7 (43.3—48.0) 52.5 (41.2—61.3) 1.14 (0.92—1.33)
4 (N = 268) 56.3 (53.1—59.8) 61.9 (50.1—73.1) 1.10 (0.87—1.28)
5 (N = 268) 74.7 (68.4—84.9) 81.9 (65.0—96.6) 1.05 (0.86—1.22)
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with higher BUN, high creatinine and lower hemoglobin
had higher CrCl/iGFR ratio. The only other factors asso-
ciated with the CrCl/iGFR ratio were the use of loop di-
uretics (associated with higher CrCl/iGFR ratio of 0.09,
p = 0.001) and hemoglobin A1C (each 1% increase in
hemoglobin A1c was associated with a 0.02 lower CrCl/
iGFR ratio, p = 0.007). There was no association with use
of thiazide diuretics.
There was no significant correlation between degree of
albuminuria and ratio of CrCl/iGFR (rs = 0.02, p = 0.40
in Spearman’s correlation test) (Figure 1). In unadjusted
models, categories of albuminuria were not associated
with higher CrCl/iGFR ratios (Table 3). Results were un-
changed in multivariable analyses controlling for age,
sex, race/ethnicity, use of loop diuretics and hemoglobin
A1c levels (Table 3). Even patients with ≥ 3000 mg of
24-hour urine albumin did not appear to have increased
tubular secretion of creatinine compared to normal albu-
minuria group. Additionally, CrCl/iGFR ratio in patients
(N = 47) with serum albumin <3.0 g/dl was 1.21 ± 0.48Figure 1 Scatter plot with a locally weighted scatterplot smoothing li
CrCl/iGFR (rs = 0.02, P = 0.40 by Spearman’s correlation test) (two outand that in with serum albumin ≥3.0 g/dl (N = 1260) was
1.19 ± 0.48 (p-value 0.89). Also there was no association
between degree of albuminuria and the ratio of CrCl/
iGFR within substrata of iGFR level (data not shown).
Mean CrCl/iGFR was not significantly different be-
tween non-Hispanic black and non-Hispanic white pa-
tients (Table 4). The results were similar after further
adjusting for age, sex, race/ethnicity, use of loop diuretics
and hemoglobin A1c levels. CRIC participants who were
Hispanic also did not have statistically different CrCl/
iGFR ratios compared with non-Hispanic white partici-
pants (Table 4). There was no association between race/
ethnicity and the ratio of CrCl/iGFR within substrata of
iGFR level.
Similar results were seen in a sensitivity analysis using
log-transformed CrCl/iGFR ratio as the outcome (data
not shown).
Discussion and conclusions
In this well characterized cohort of CKD patients with
mean measured GFR of 48 m/min/1.73 m2, we found thatne showing that 24-hrs urinary albumin is not correlated with
lier with CrCl/iGFR ratio of 6.71, 0.04 were omitted).
Table 3 The association of 24-hrs urinary albumin in categorical classifications and CrCl/iGFR ratio in the regression
model (N = 1342)
Normal (24-hrs urine
albumin < 30 mg;
N = 515)
Microalbuminuria (24-hrs
urine albumin 30 to
≦299 mg; N = 343)
Macroalbuminuria (24-hrs
urine albumin 300 to
≦2999 mg; N = 378)
Nephrotic-range proteinuria
(24-hrs urine albumin
≧3000 mg; N = 106)
Absolute change in
CrCl/iGFR (95% CI)
Unadjusted Reference 0.05 (−0.01—0.12) 0.02 (−0.04—0.09) 0.07 (−0.04—0.17)
P = 0.12 P = 0.48 P = 0.20
Multivariate adjusteda Reference 0.06 (−0.01—0.13) 0.05 (−0.03—0.12) 0.11 (−0.01—0.22)
P = 0.08 P = 0.21 P = 0.07
CrCl = Creatinine clearance; IGFR = I125 Iothalamate measured glomerular filtration rate.
aAdjusted for age, sex, race/ethnicity, use of loop diuretics, hemoglobin A1C levels.
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rably lower than that reported by older papers in the litera-
ture (although similar to certain more recently published
studies [18]). For example, in a frequently cited article
based on 171 patients, Shemesh et al. reported that in the
range of measured GFR of 40-80 ml/min/1.73 m2 (mean
60 ml/min/1.73 m2) the CrCl/GFR ratio was 1.57 [7,19,20].
Bauer et al. described CrCl/GFR ratios of 1.62-1.87 when
measured GFR was 40-70 ml/min/1.73 m2 [3]. Reasons for
this potential difference may include the fact that both
Shemesh and Bauer measured GFR using inulin clearance
rather than iothalamate clearance and the former is known
to be lower than the latter [21]. A second possibility is that
prior CrCl values may be artifactually high as a result of
serum creatinine calibration measurement problems which
were not fully appreciated in prior studies. Another hy-
pothesis is that CrCl/GFR ratio varies by patient character-
istics. For example, the Shemesh paper only included
patients with glomerular disease who presumably had
greater proteinuria than the CRIC enrollees, although the
degree of proteinuria was not reported.
Indeed some prior papers suggested that CrCl/GFR ra-
tio increases at higher levels of proteinuria. Carrie et al.
reported that the CrCl/GFR ratio was 1.22 for 10 pa-
tients with cardiac failure (and mean inulin clearance
of 47 ml/min/1.73 m2) but it was 1.70 for 38 patientsTable 4 CrCl = creatinine clearance; IGFR = I125 Iothalamate m
Non-Hispanic white
(N = 568)
Absolute change in CrCl/iGFR ratio (95% CI)
Unadjusted Reference
Multivariate adjusteda Reference
CrCl = Creatinine clearance; iGFR = I125 Iothalamate measured glomerular filtration ra
Others = American Indian/Alaskan Native, Asian/Asian American, or Native Hawaiian
aAdjusted for age, sex, use of loop diuretics, hemoglobin A1C.with nephrotic syndrome (and mean inulin clearance of
42 ml/min/1.73 m2) [22]. Branten et al. reported that in
42 patients with nephrotic syndrome (mean GFR 54 ml/
min/1.73 m2), hypoalbuminemia was associated with more
secretory clearance of creatinine and as a consequence,
overestimation of GFR by endogenous CrCl is more pro-
nounced in patients with nephrotic syndrome [4]. How-
ever, others have not observed that proteinuria influences
the CrCl/GFR ratio [23-25]. Our results do not show an
association between degree of proteinuria as assessed
by 24-hr urine albumin and CrCl/iGFR ratio. Although
the fraction of our study population with high grade
proteinuria was relatively low, because of the large
sample size, we still had more than 100 patients with
albuminuria ≥ 3000 mg/day. We also did not find any
association between hypoalbuminemia and tubular cre-
atinine secretion, although our study did not include
many patients with severe hypoalbuminemia (e.g. serum
albumin <2.5 g/dl) [4].
Our study also contributes to the literature by asses-
sing the relation between race/ethnicity and CrCl/iGFR
ratio. Blacks in the U.S. population are known to have
higher mean serum creatinine concentration than whites
[26]. Previously, based on the relatively low CrCl/iGFR
ratios (ranging from 1.01-1.21) reported out of an ex-
clusively black CKD cohort, some investigators haveeasured glomerular filtration rate
Non-Hispanic black Hispanics Others
(N = 494) (N = 188) (N = 92)
−0.03 (−0.09—0.03) 0.01 (−0.07—0.09) −0.01 (−0.12—0.09)
P = 0.34 P = 0.89 P = 0.79
−0.03 (−0.09—0.03) 0.02 (−0.07—0.10) 0.01 (−0.10—0.11)
P = 0.38 P = 0.72 P = 0.91
te.
/Other Pacific islander.
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tubular handling of creatinine [6]. Our results do not
support this hypothesis. We found that non-Hispanic
white, and non-Hispanic black (and Hispanic) CRIC par-
ticipants have similar CrCl/iGFR ratio. As alluded to be-
fore, comparing results from different publications may
be confounded by differences in the exogenous filtration
marker used to measure GFR and by serum creatinine
calibration problems.
Our finding that use of loop diuretics was associated
with higher CrCl/GFR has been noted before [27,28].
Possible mechanisms for this include reduction in GFR
due to tubule-glomerular feedback [29,30] out of pro-
portion to reduction in CrCl, hence resulting in a higher
CrCl/iGFR ratio. But this rather speculative as we are
not aware of any evidence for or against this hypothesis.
Our report that HgA1c is associated with the CrCl/iGFR
ratio is novel. However, since we screened for a large
number of associations, we cannot rule out that this
result is due to chance and should be evaluated in fu-
ture studies.
We confirmed there was an inverse correlation be-
tween CrCl/iGFR with iGFR. This is consistent with
the prior literature which showed that at progressive
more severe degrees of CKD, tubular secretion of creatin-
ine plays an increasing prominent role in clearance
[3,28,31-33]. We interpreted the observation that CKD
patients with higher BUN, high creatinine and lower
hemoglobin had higher CrCl/iGFR ratio as being because
higher BUN, high creatinine and lower hemoglobin re-
flect lower GFR values.
The strengths of our study are numerous and include
a large, diverse sample, the wide range of GFR, the as-
sessment of proteinuria using albuminuria, the calibra-
tion of serum creatinine measurements to an external
accepted international gold standard, and the uniform
assessment of GFR and CrCl across racial/ethnic groups
which provide reliable information about potential ra-
cial/ethnic differences.
Limitations of our study include that iGFR and CrCl
were not measured using the same UV/P blood and
urine samples. Certain intrinsic renal diseases were not
represented by study design such as polycystic kidney
disease or myeloma kidney. We do not have informa-
tion on use of trimethoprim and cimetidine, although
the use of these medications are likely to be infre-
quent. Inaccuracies in 24-hour urine collection may
have introduced random error and biased results to-
wards the null. We did have to exclude some CRIC
enrollees who were missing 24-hour albumin measure-
ments but this should not have introduced bias given the
small fraction (<6%). Our study was cross-sectional so we
do not have information regarding evolution of CrCl/iGFR
over time.There are several implications of our study results.
One, the CrCl/iGFR ratio is closer to 1.0 than reported
by several frequently cited reports in the literature. So
CrCl is closer to GFR better than the impression given
by those some papers. Two, it is reassuring that factors
such as degree of proteinuria (or others variables listed
in Table 1) do not strongly influence CrCl/GFR ratio.
Because if a multitude of factors influenced the CrCl/
GFR ratio, then it would make it ever more challenging
to rely on serum creatinine to estimate GFR. Three, we
hope this line of work will bring fresh attention to cre-
atinine secretion. Better understanding of determinants
of creatinine secretion may have implications as a recent
study reported that variants in the gene coding organic
cation tranporter 2 influences both net tubular creatin-
ine secretion and risk of end-stage renal disease [18].
To conclude, using calibrated creatinine measurements
and iothalamate clearance to define GFR, we quantified
the ratio of CrCl/iGFR in a large modern cohort. To our
knowledge, this the largest study quantifying this important
aspect of renal physiology.
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